Gilead’s Remdesivir AKA Velkury has emergency use authorization (EUA) n the United States and just barely reduces hospital length of stay in some patients and it is questionable if it really reduces mortality to any degree. It has NOT received FDA approval because it hasn’t performed in real life practice. As soon as the FDA sees another drug that can reduce length of stay and save some lives, Remdesivir will lose it’s EUA and it’s share of the market which is pretty much all of it.
Remdesivir needs Brilacidin, but it is abundantly clear that Brilacidin does not need Remdesivir. I anticipate the placebos will be whatever the standard of care is being used in the respective country as it is unethical to withhold treatment in a life or death situation. Brilacidin will go head to head vs. Remdesivir and we all know who will win.
Efftiabdunnsunnylemonturds!
(7)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.